United States Patent 8,546,367 (DCA 14C Content Threshold): Scope, Claims, and US Patent Landscape
What does US 8,546,367 claim cover?
US Patent 8,546,367 claims compositions and a use method centered on a specific material-quality parameter for deoxycholic acid (DCA): radiocarbon (14C) content below defined parts-per-trillion (ppt) levels. The patent scope is anchored on two elements:
- Drug substance identity: “deoxycholate” (and, in dependent claim language, “DCA”)
- Purity/verification parameter: 14C content < 1 ppt, with dependent fall-backs at < 0.9 ppt and product embodiments at 0.87, 0.88, 0.89 ppt
The claims also cover formulation embodiments (including aqueous compositions and inclusion of phosphatidyl choline) and one method claim tied to fat cell removal using a DCA salt having the same 14C limit.
Claim set (as provided)
Independent / core structure
- Claim 1: Composition comprising deoxycholate + pharmaceutically acceptable excipient/carrier, where deoxycholate has 14C < 1 ppt
- Claim 3: Aqueous pharmaceutical composition comprising deoxycholate + pharmaceutically acceptable excipient/carrier, 14C < 1 ppt
- Claim 5: Aqueous pharmaceutical composition comprising deoxycholate + phosphatidyl choline + excipient/carrier, 14C < 1 ppt
- Claim 16: Method for removing fat cells by contacting fat cells with an effective amount of a pharmaceutically acceptable salt of DCA, where the DCA has 14C < 1 ppt
Dependent tightening
- Claim 2 / 4 / 6: Same as claims 1 / 3 / 5, with 14C < 0.9 ppt
- Claims 7-15: Same base compositions with explicit 14C “spot” values (0.87, 0.88, 0.89 ppt), distributed across claims 1, 3, 5
How broad is the scope?
Material-quality gatekeeper: the 14C threshold drives claim scope
For composition and method coverage, the dispositive variable is the 14C content of the deoxycholate/DCA. Everything else is either:
- generic (“pharmaceutically acceptable excipient and/or carrier”), or
- limited by a formulation add-on in one branch (“phosphatidyl choline”), or
- limited to the biological target/action in the method claim (“removing fat cells” via contacting with a DCA salt).
That structure makes the patent less about formulation mechanics and more about sourcing/grade identity of the DCA raw material as proven by a validated 14C assay.
Composition breadth by “excipient/carrier” language
Claims 1, 3, and 5 each allow “at least one pharmaceutically acceptable excipient and/or carrier” without listing constraints. That generally captures:
- aqueous vehicles
- buffers and tonicity agents
- stabilizers
- viscosity modifiers
- delivery aids
Only phosphatidyl choline is specifically required in claim 5.
Aqueous limitation narrows without removing breadth within water-based products
Claim 3 and 5 require “aqueous pharmaceutical composition.” That covers:
- solutions
- suspensions/emulsions if they qualify as “aqueous pharmaceutical composition” in practice and claim construction
- buffered systems
It does not, on its face, cover non-aqueous or purely oil-based vehicles unless an accused product is argued to still meet “aqueous pharmaceutical composition” during infringement analysis.
Method claim breadth is tied to “contacting” and “effective amount”
Claim 16 covers “contacting said fat cells” with an effective amount of a pharmaceutically acceptable salt of DCA, with 14C < 1 ppt.
That language can map to multiple delivery modalities if they involve direct or proximate contact of DCA salt with fat cells and are characterized as a method of removing fat cells. The independent novelty sits in the 14C quality of the DCA salt.
Numeric fallbacks create a layered infringement test
By including both:
- a “less than” range (less than 1 ppt; less than 0.9 ppt)
- and explicit points (0.87 / 0.88 / 0.89 ppt)
the patent creates multiple trigger possibilities. A challenger must address whether the accused DCA meets any claimed 14C threshold (or an explicit value embodiment), and whether the measurement methodology aligns with claim interpretation.
Claim-by-claim scope map (practical infringement elements)
Claims 1–2: Composition, DCA/deoxycholate 14C < 1 ppt (or < 0.9 ppt)
Infringement elements
- A composition containing deoxycholate
- Contains at least one pharmaceutically acceptable excipient or carrier
- Deoxycholate has 14C less than the threshold
Breadth
- High tolerance on excipient/carrier
- No formulation-specific constraints beyond the general inclusion of excipient/carrier
Claims 3–4: Aqueous composition, 14C < 1 ppt (or < 0.9 ppt)
Infringement elements
- Aqueous composition
- Deoxycholate + excipient/carrier
- 14C < 1 ppt (or < 0.9 ppt)
Breadth
- Large within aqueous systems
- Still excludes non-aqueous formulations if “aqueous” is interpreted strictly
Claims 5–6: Aqueous composition including phosphatidyl choline, 14C < 1 ppt (or < 0.9 ppt)
Infringement elements
- Aqueous composition
- Deoxycholate + phosphatidyl choline
- Excipient/carrier
- 14C threshold
Breadth
- More specific than claims 1–4
- Captures a subset of DCA-based formulations that include phosphatidyl choline
Claims 7–15: Explicit 14C values (0.87, 0.88, 0.89 ppt)
These dependent claims function as:
- additional infringement anchors for products whose DCA is tested/qualified at those values, and
- evidentiary focus points in litigation (numeric embodiments can simplify claim matching when assay results align to those values).
Distribution across base claim categories:
- For < 1 ppt base (claim 1 family): claims 7–9 and also 13–15 under claim 5 family
- For aqueous base (claim 3 family): claims 10–12
Claim 16: Method of removing fat cells via DCA salt, 14C < 1 ppt
Infringement elements
- Method for removing fat cells
- Contacting fat cells with an effective amount of a pharmaceutically acceptable salt of DCA
- DCA has 14C < 1 ppt
Breadth
- Allows DCA salt forms (as salts) if “pharmaceutically acceptable”
- Uses “contacting” rather than a specific injection/delivery phrasing in the claim text you supplied
- Still hinges on proving the 14C status of the DCA salt in the administered material
What does this mean for freedom-to-operate (FTO)?
Infringement risk is primarily a function of DCA 14C qualification
For an accused product or process to avoid infringement, it must generally avoid satisfying the 14C < 1 ppt condition in the claimed material. If a competitor uses DCA with 14C at or above 1 ppt (or uses a deoxycholate-like ingredient that does not meet “deoxycholate” claim construction), the patent’s central gating condition is not met.
Formulation design-around is possible but may be secondary
Because claims 1–4 largely ignore excipient/carrier identity, formulation-only design around is limited:
- Removing phosphatidyl choline can avoid claim 5/6 and the dependent claim cluster tied to claim 5.
- But that does not avoid claims 1–4 if the product is aqueous and contains deoxycholate meeting the 14C threshold.
Method avoidance is also gated by DCA 14C
A competitor could try to design a different method pathway for fat cell removal, but claim 16 is still likely to be implicated if the accused method includes contacting fat cells with a DCA salt and the DCA salt satisfies 14C < 1 ppt.
US patent landscape: how this kind of claim typically positions relative prior art and “around” activity
Landscape topology around DCA-based products
Within US practice, DCA-related patents and product development typically cluster around:
- formulation composition and delivery format
- mechanisms of action in fat tissue
- manufacturing and characterization of active ingredients
- method-of-use claims (fat reduction, localized adipose treatment, etc.)
This patent’s distinctive attribute is the radiocarbon (14C) content threshold. That tends to shift the competitive landscape from “what is in the syringe” to “how the active substance is sourced and certified.”
Strategic implication for competitors
- If the competitor uses DCA sourced from a different carbon history such that 14C is not below 1 ppt, the claim may be avoided even if formulation and method match.
- If the competitor’s DCA is within the claimed 14C range, switching excipients or removing phosphatidyl choline can reduce risk only for the phosphatidyl choline subset (claims 5–6, 13–15), not for claims 1–4 and claim 16.
Likely chokepoints in an FTO review
In litigation or design around, the most important factual and technical record points are:
- 14C assay methodology (what measurement approach was used to characterize the DCA/deoxycholate batches)
- batch-to-batch comparability (whether 14C varies across lots)
- stability and storage effects (whether handling changes effective measured 14C)
- form of active (salt identity for claim 16, and whether deoxycholate vs DCA is treated as the same asserted material in claim construction)
Scope summary (what is covered vs. what is not, based on your claim text)
Covered (high confidence based on claim language provided)
- Any composition containing deoxycholate with 14C < 1 ppt, regardless of excipient/carrier selection
- Any aqueous version of the above (claims 3–4)
- Any aqueous version that includes phosphatidyl choline (claims 5–6)
- Fat-cell removal methods using a pharmaceutically acceptable salt of DCA with 14C < 1 ppt (claim 16)
- Specific 14C embodiments at 0.87, 0.88, 0.89 ppt (claims 7–15)
Not clearly covered (based on claim wording provided)
- Non-aqueous formulations (would not meet the “aqueous pharmaceutical composition” requirement in claims 3 and 5; claim 1 may still cover if “composition” is non-aqueous and does not require aqueous)
- Products where deoxycholate/DCA 14C is not below 1 ppt
- Methods where the active is not a “pharmaceutically acceptable salt of DCA,” or where the fat-cell contact requirement is not met as construed
- Phosphatidyl choline-free aqueous products still can infringe claims 1–4 if 14C < 1 ppt is met
Key Takeaways
- US 8,546,367 is an active-material characterization patent: the claims hinge on radiocarbon (14C) content of deoxycholate/DCA, not on broad excipient/formulation diversity.
- Claims 1 and 3 cover compositions and aqueous compositions with deoxycholate 14C < 1 ppt; claim 5 narrows to inclusion of phosphatidyl choline.
- Dependent claims tighten to < 0.9 ppt and add numeric embodiments at 0.87 / 0.88 / 0.89 ppt.
- The method claim 16 covers fat-cell removal by contacting with a DCA salt having 14C < 1 ppt, leaving excipient or delivery differences secondary to the 14C status of the active.
- For FTO, the decision variable is whether the competitor’s DCA batch quality meets the claimed < 1 ppt gate; excipient swaps alone may not avoid claims 1–4 and claim 16.
FAQs
1) Is this patent about DCA mechanism or formulation technology?
It is primarily about material qualification using 14C content for deoxycholate/DCA, with formulation coverage tied to general excipient/carrier language and one specific excipient inclusion (phosphatidyl choline).
2) What is the broadest claim?
Claim 1: a composition with deoxycholate and pharmaceutically acceptable excipient/carrier where 14C < 1 ppt.
3) Does removing phosphatidyl choline avoid the patent?
It can avoid claim 5/6 and dependent claim branches that require phosphatidyl choline, but it does not avoid claims 1–4 if the formulation contains deoxycholate with 14C < 1 ppt.
4) Can a competitor avoid infringement by changing excipients?
Claims 1–4 use broad “excipient and/or carrier” language, so excipient changes alone do not remove risk if deoxycholate 14C remains < 1 ppt.
5) How does the method claim 16 change the FTO picture?
Claim 16 targets fat-cell removal by contacting with a DCA salt having 14C < 1 ppt, so method design-around still hinges on the 14C qualification of the administered DCA salt.
References
[1] United States Patent 8,546,367 (claim text provided by user).
